Among treatment‐naïve individuals with chronic HCV infection and without cirrhosis, glecaprevir‐pibrentasvir for eight weeks is recommended. The aim of this analysis was to evaluate the efficacy of glecaprevir‐pibrentasvir for six weeks in people with acute and recent HCV infection. In this open‐label single‐arm multicentre international pilot study, adults with recent HCV (duration of infection <12 months) received glecaprevir‐pibrentasvir 300mg‐120mg daily for six weeks. Primary infection was defined by first positive anti‐HCV antibody and/or HCV RNA within six months of enrolment and either acute clinical hepatitis within the past 12 months (symptomatic seroconversion illness or ALT>10xULN) or anti‐HCV antibody seroconversion within 18 months. Reinfection was defined as new positive HCV RNA within six months of enrolment and evidence of prior spontaneous or treatment‐induced clearance. The primary endpoint was sustained virologic response at 12 weeks post‐treatment (SVR12). Thirty men (median age 43 years, 90% men‐who‐have‐sex‐with‐men) received treatment, of whom 77% (n=23) were HIV‐positive, 47% (n=14) had ever injected drugs, and 13% (n=4) had HCV reinfection. The majority had HCV genotype 1 (83%, n=25), followed by genotype 4 (10%, n=3) and genotype 3 (7%, n=2). At baseline, median estimated duration of infection was 29 weeks (range 13, 52) and median HCV RNA was 6.2 log10 IU/mL (range 0.9, 7.7). SVR12 in the intention‐to‐treat and per‐protocol populations was achieved in 90% (27/30) and 96% (27/28), respectively. There was one case of relapse and two cases of non‐virological failure (death, n=1; loss to follow up, n=1). No treatment‐related serious adverse events were seen.